65,437 trials
Burnout, Professional · Burnout Syndrome
Primary: The Change in the Emotional Exhaustion (EE) Burnout Score(as Measured by the Maslach Burnout Inventory (MBI)From Baseline to End of Each Exercise Phase. — 20.95348837…
Critical Limb Ischemia
Primary: Treatment-related Adverse Events (TEAE) Reporting of RJX — 2; 1; 2; 0 Participants
Cataract · Pain · Ocular Inflammation
Primary: Number of Participants With Complete Resolution of Anterior Chamber (AC) Cells at Visit 5 (Postoperative Day 8) — 40; 52; 61 Participants
Influenza
Primary: Number and Percentage of Seroconverted Participants at 21 Days Post-vaccination — 413; 216; 411; 201 Participants
Abnormal Liver Function
Primary: Pre-processing Length of the Longest Piece (LLP) — 1.47; 2.09 centimeter
Environmental Exposure · Nasal Inflammation
Primary: Change in % Polymorphonuclear Leukocytes (PMN) in Nasal Lavage Fluid Immediately Post-Exposure From Baseline — -1.02; -6.8 percent PMNs in nasal lavage fluid
Healthy Volunteers
Primary: Safety and Tolerability as Measured by Adverse Events — 0; 0; 0; 0 participants
Non-Hodgkin Lymphoma · Burkitt's Lymphoma · Chronic Lymphocytic Leukemia
Primary: Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Essential Hypertension
Primary: Change From Baseline to End of Double-blind Treatment in Sitting Diastolic Blood Pressure at Trough — 97.5; 97.8; 97.7; 97.8 mmHg — p=<0.001
Constipation Predominant Irritable Bowel Syndrome
Primary: Percentage of Subjects With Overall Response for 6 Out of 12 Weeks — 107; 71 Participants — p=<0.001
Type II Diabetes Mellitus · Renal Insufficiency
Primary: Percent Change From Baseline in Plasma Glucose Area Under the Concentration Time-curve From Time 0 to 4 Hours (AUC0-4 Hrs) as Measured by Mixed-meal Tolerance Test…
Morbid Obesity · Obstructive Sleep Apnea Syndrome · Metabolic Syndrome
Primary: Percentage of Excess Weight Change (EWL) — -35.5 percent change
Perinatal Depression · PostPartum Depression
Primary: The Change in QIDS-16 Scores From Baseline to 24 Weeks Postpartum — 5.9; 5.3; 5.8; 6.4 score on a scale
Sickle Cell Anemia · Sickle Cell-Beta0-Thalassemia
Primary: Change From Baseline to 4 Weeks in Soluble Vascular Cell Adhesion Molecule-1 (VCAM-1) — 40.9; 10.7 pg/mL — p=0.6281
Myopia · Safety Issues
Primary: Corneal Biomechanics in Terms of Corneal Hysteresis and Resistance Factor — 11.12; 11.10; 10.37; 11.20 mmHg